H0RSHOLM, Denmark--(BUSINESS WIRE)--LifeCycle Pharma A/S (OMX: LCP), an emerging specialty pharmaceutical company, announced today that interim results based on 10 patients, as part of an ongoing Phase II clinical trial for LCP-Tacro, an immunosuppressant for the treatment of kidney transplant patients, demonstrated a superior profile when compared to Prograf®, including better pharmacokinetics (PK), once-a-day tablet formulation and higher bioavailability. Prograf® is currently marketed worldwide by Astellas Pharma as twice-a-day capsules of tacrolimus.
